CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
Show more...
CEO
Mr. Anup Radhakrishnan
직원
167
국가
미국
ISIN
US14179K1016
상장
0 Comments
생각을 공유하기
FAQ
오늘 CARGO Therapeutics 주가는 얼마인가요?▼
CRGX의 현재 가격은 $4.47 USD이며, 지난 24시간 동안 -1.54% 하락했습니다. 차트에서 CARGO Therapeutics 주가 흐름을 자세히 살펴보세요.
CARGO Therapeutics의 주식 심볼은 무엇인가요?▼
거래소에 따라 주식 심볼이 다를 수 있습니다. 예를 들어, XNAS 거래소에서는 CARGO Therapeutics 주식이 CRGX 심볼로 거래됩니다.